Cytosorbents’ (CTSO) Neutral Rating Reiterated at HC Wainwright

Cytosorbents (NASDAQ:CTSO)‘s stock had its “neutral” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $1.00 target price on the medical research company’s stock. HC Wainwright’s price target would suggest a potential upside of 14.69% from the company’s previous close.

Separately, StockNews.com began coverage on Cytosorbents in a report on Thursday, May 2nd. They issued a “hold” rating for the company.

Cytosorbents Price Performance

CTSO opened at $0.87 on Tuesday. Cytosorbents has a 1 year low of $0.78 and a 1 year high of $4.29. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.77 and a quick ratio of 1.51. The company has a market capitalization of $47.35 million, a price-to-earnings ratio of -1.36 and a beta of 0.62. The firm’s fifty day moving average price is $0.91 and its two-hundred day moving average price is $1.12.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. The business had revenue of $8.67 million for the quarter, compared to analysts’ expectations of $9.29 million. As a group, analysts anticipate that Cytosorbents will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CTSO. Key Client Fiduciary Advisors LLC lifted its stake in Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 22,557 shares during the last quarter. Raymond James & Associates bought a new stake in shares of Cytosorbents in the fourth quarter valued at $56,000. Chicago Partners Investment Group LLC lifted its position in shares of Cytosorbents by 84.0% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 36,358 shares of the medical research company’s stock valued at $67,000 after buying an additional 16,598 shares during the last quarter. Sargent Investment Group LLC grew its stake in shares of Cytosorbents by 4.1% during the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after acquiring an additional 51,699 shares during the period. Finally, Neuberger Berman Group LLC increased its holdings in Cytosorbents by 19.9% in the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares during the last quarter. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.